3,560 material Form 8-K filings that 2,489 companies we cover made with the SEC in October 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 2,508 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Healthcare Triangle, Inc. received a Nasdaq Staff Delisting Determination because its closing bid price has been below $1.00 and the company is not eligible for a compliance period after cumulative reverse stock splits of 1-for-14,940 over two years. The company intends to request a Panel hearing, which would stay suspension, and its shares continue to trade as HCTI for now, but without a successful appeal the stock would be suspended from Nasdaq on October 12, 2026.
Nasdaq notice dated October 1, 2026 cites failure to meet the $1.00 minimum bid price under Rule 5550(a)(2)
Company is ineligible for a compliance period after a 1-for-249 reverse split (August 1, 2025) and a 1-for-60 reverse split (February 10, 2026)
Appeal to a Nasdaq Hearings Panel must be requested by October 8, 2026; otherwise trading suspension begins October 12, 2026
Company intends to request a hearing and may propose a reverse stock split; the Panel's outcome is not assured
On October 1, 2026, Tonix Pharmaceuticals received notice that Dr. Reddy's Laboratories had filed an ANDA with the FDA for a generic version of TONMYA, challenging four Orange Book patents. The filing matters to shareholders because it signals possible generic competition for TONMYA, and the company says it intends to vigorously enforce its intellectual property rights but cannot predict the outcome.
Notice received October 1, 2026 from Dr. Reddy's Laboratories Ltd. and Dr. Reddy's Laboratories, Inc.
ANDA covers a generic version of TONMYA (cyclobenzaprine hydrochloride) sublingual tablets, 2.8 mg, with a Paragraph IV certification
Certification targets U.S. Patent Nos. 9636408, 9956188, 10117936 and 10864175, all listed in the Orange Book
A patent infringement suit filed within 45 days of the notice would automatically block FDA approval of the ANDA for up to 30 months, subject to the outcome of litigation
Xcel Brands, Inc. received a letter from Nasdaq on September 29, 2026, saying its common stock closed below $1.00 per share for 30 consecutive business days, so it does not meet the minimum bid price requirement. The company has until March 29, 2027 to regain compliance, which requires a closing bid price of at least $1.00 for 10 consecutive business days; if it cannot, its shares could face delisting from the Nasdaq Capital Market.
Nasdaq notice dated September 29, 2026 cites a bid price below $1.00 for 30 consecutive business days.
Compliance period runs 180 calendar days, until March 29, 2027.
Regaining compliance requires a closing bid of at least $1.00 for 10 consecutive business days.
A reverse stock split may be needed; the company says there is no assurance it will regain compliance.
BeyondSpring Inc. received a Nasdaq notice on September 29, 2026, stating its market value of listed securities has been below $35 million for 30 consecutive business days, so it no longer meets the continued listing requirement. The notice does not cause immediate delisting, and shares continue to trade on Nasdaq, but the company must regain compliance by March 29, 2027, or face a delisting process, which the company says it cannot assure.
Nasdaq notice received September 29, 2026 under Listing Rule 5550(b)(2)
Market value of listed securities fell below $35 million for 30 consecutive business days
Compliance period runs 180 calendar days, until March 29, 2027
Shares continue to trade on Nasdaq during the compliance period
A federal court in California ruled on September 29, 2026, on motions to dismiss in the lawsuit Joby Aero brought against Archer and an employee. The court narrowed the claims, dismissing some trade-secret and contract claims, some with leave to amend, while letting other claims proceed. The court also dismissed Archer's counterclaims against Joby without leave to amend, which limits Archer's own claims in the case.
Ruling date: September 29, 2026, U.S. District Court for the Northern District of California, Case No. 5:25-cv-10703-SVK
Certain trade-secret and contract-related claims against Archer and its employee were dismissed, some with leave to amend
Archer's counterclaims against Joby Aero and Joby Aviation under the Lanham Act and California's Unfair Competition Law were dismissed without leave to amend
Daré Bioscience received a Nasdaq letter dated September 28, 2026, stating that its common stock closed below the $1.00 minimum bid price for 30 consecutive business days. The letter has no immediate effect on the stock's listing, but the company has until March 29, 2027 to regain compliance, and failure to do so could lead to delisting proceedings unless it qualifies for an additional compliance period.
Nasdaq letter received September 28, 2026 cites the $1.00 minimum bid price requirement under Listing Rule 5550(a)(2)
Compliance Date is March 29, 2027, a 180-calendar-day initial period
Regaining compliance requires a closing bid price of at least $1.00 for 10 consecutive business days, unless Nasdaq extends that period
A reverse stock split may be needed if the company seeks an additional 180-day period; the company states there is no assurance it will regain compliance
Solesence, Inc. received a Nasdaq notice on September 29, 2026 stating its stock closed below $1.00 per share for 30 consecutive trading days, so it no longer meets Nasdaq's minimum bid price rule. The notice has no immediate effect on the stock's listing, but the company must regain compliance by March 29, 2027, or face possible delisting, and it says there is no assurance it will do so.
Nasdaq notice dated September 29, 2026; stock below $1.00 for 30 consecutive trading days
Initial compliance period of 180 calendar days, ending March 29, 2027
To regain compliance, closing bid must be at or above $1.00 for at least 10 consecutive trading days before March 29, 2027
Company may get an additional 180-day grace period if it meets listing criteria and notifies Nasdaq of its intent to cure
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.